LITESPARK-011最终预设分析:贝组替尼联合仑伐替尼对比卡博替尼治疗抗PD-(L)1后晚期肾细胞癌
LITESPARK-011是一项3期随机开放标签试验,入组抗PD-(L)1治疗后进展的晚期透明细胞肾细胞癌成人患者,1:1随机接受贝组替尼联合仑伐替尼或卡博替尼治疗。最终分析显示联合组较卡博替尼继续改善无进展生存期(HR 0.74,95%CI 0.62-0.88)、客观缓解率(53.1% vs 40.2%)和缓解持续时间(22.0 vs 11.9个月),总生存期虽倾向联合组但未达统计学显著性(中位33.7 vs 28.6个月;HR 0.85,95%CI 0.70-1.03;单侧P=0.04689,预设界值0.0223)。
要点
- 贝组替尼联合仑伐替尼较卡博替尼显著改善PFS(HR 0.74)和ORR(53.1% vs 40.2%)。
- 最终分析OS倾向联合组但未达预设统计学显著性界值(P=0.04689 vs 0.0223)。
- 联合组≥3级治疗中出现不良事件发生率85.4%,与卡博替尼组83.0%相近。
核心结论
- 贝组替尼联合仑伐替尼较卡博替尼在抗PD-(L)1治疗后晚期ccRCC中持续显示PFS、ORR和DOR获益,OS倾向联合组但最终分析未达统计学显著性。
- 联合组安全性特征与各药单药治疗一致,结果继续支持该联合作为抗PD-(L)1治疗后晚期ccRCC的治疗选择。
研究设计与样本
- 3期随机开放标签LITESPARK-011试验(NCT04586231),入组抗PD-(L)1治疗后进展的晚期透明细胞肾细胞癌成人患者。
- 按1:1随机分配至贝组替尼120 mg联合仑伐替尼20 mg口服每日一次,或卡博替尼60 mg口服每日一次,直至疾病进展或不可接受的不良事件。
- 双主要终点为盲态独立中心审查(BICR)评估的PFS和OS;BICR评估的ORR为关键次要终点,安全性和BICR评估的DOR为次要终点。
- 最终分析时随机至数据截止日期(2026年2月2日)的中位时间为38.8个月(范围29.1-59.0),贝组替尼联合仑伐替尼组371例,卡博替尼组376例。
主要发现
- 贝组替尼联合仑伐替尼组较卡博替尼组持续显示PFS获益(HR 0.74,95%CI 0.62-0.88)。
- ORR为53.1% vs 40.2%,DOR为22.0 vs 11.9个月。
- 成熟OS结果在最终分析未达统计学显著性(中位33.7 vs 28.6个月;HR 0.85,95%CI 0.70-1.03;单侧P=0.04689,预设界值0.0223)。
- ≥3级治疗中出现不良事件发生率在贝组替尼联合仑伐替尼组为85.4%,卡博替尼组为83.0%。
临床怎么用
- 对于抗PD-(L)1治疗后进展的晚期透明细胞肾细胞癌患者,贝组替尼联合仑伐替尼可作为治疗选择之一。
- 该联合方案在PFS、ORR和DOR方面优于卡博替尼,但OS未达统计学显著性,临床决策需综合获益与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The phase 3, randomized, open-label LITESPARK-011 trial (NCT04586231) investigated belzutifan plus lenvatinib versus cabozantinib in participants with advanced clear-cell renal-cell carcinoma (ccRCC) following anti-PD-(L)1 therapy. At earlier analyses, belzutifan plus lenvatinib significantly improved progression-free survival (PFS) and objective response rate (ORR) versus cabozantinib. Overall survival (OS) was tested but did not reach significance. We present the final analysis of LITESPARK-011. PARTICIPANTS AND METHODS: Adult participants with advanced ccRCC that progressed on or after anti-PD-(L)1 therapy were randomly assigned (1:1) to 120 mg belzutifan plus 20 mg lenvatinib or 60 mg cabozantinib orally once daily until disease progression or unacceptable adverse events. Dual primary endpoints were PFS by blinded independent central review (BICR) and OS. ORR by BICR was a key secondary endpoint; safety and duration of response (DOR) by BICR were secondary endpoints. RESULTS: At final analysis, median time from randomization to data cutoff date (2 February 2026) was 38.8 months (range, 29.1-59.0). 371 participants were assigned to belzutifan plus lenvatinib and 376 to cabozantinib. Belzutifan plus lenvatinib continued to demonstrate benefit versus cabozantinib in PFS (HR 0.74, 95% CI 0.62-0.88), ORR (53.1% vs 40.2%), and DOR (22.0 vs 11.9 months). Mature OS results did not reach statistical significance at final analysis (median 33.7 versus 28.6 months; HR 0.85, 95% CI 0.70-1.03; one-sided P=0.04689 [prespecified boundary 0.0223]). Grade ≥3 treatment-emergent adverse events occurred in 85.4% of the belzutifan plus lenvatinib group versus 83.0% of the cabozantinib group. CONCLUSIONS: Belzutifan plus lenvatinib continued to demonstrate PFS, ORR, and DOR benefit versus cabozantinib with additional follow-up; OS favored the combination but did not reach statistical significance at final analysis. Safety profile of belzutifan plus lenvatinib remained consistent with each drug as monotherapy. These findings continue to support belzutifan plus lenvatinib as a treatment option in advanced ccRCC following anti-PD-(L)1 therapy.
引用
- Heng DYC, Schmidinger M, McDermott R, et al. Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti-PD-(L)1 therapy. Ann Oncol. 2026. PMID: 42927855. doi:10.1016/j.annonc.2026.10.109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。